From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

Drugs Real World Outcomes · 2026 · PMC13287194 · PMID 42105061

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the earlier disease setting, the recently presented AMPLITUDE trial in HRRm metastatic castration-sensitive prostate cancer showed that niraparib plus AAP versus placebo plus AAP significantly improved rPFS and showed a trend toward an OS benefit at the first interim analysis [ 30 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.